Dr. Shefali Agarwal is an experienced executive in the biotechnology and pharmaceutical industry, with nearly 20 years of expertise spanning drug development, clinical research, commercial strategy, and regulatory affairs. As a trained physician, she combines medical, business, and public health knowledge, enabling her to lead and contribute to innovative projects across various therapeutic areas, including oncology, immunology, hematology, neurology, cardiovascular diseases, and more. Her career encompasses all stages of drug development, from preclinical to post-marketing, with a deep understanding of medical and regulatory processes, ranging from Investigational New Drug (IND) applications to New Drug Applications (NDA).Currently, she serves on the boards of Fate Therapeutics, Gritstone Bio, ITBMed, and as member of the Scientific Advisory Board Committee (SABC) at Imvax.

Before joining Sironax, Dr. Agarwal was the President, CEO, and Chair of the Board at Onxeo S.A., a clinical-stage biotechnology company focused on developing drugs targeting DNA Damage Response (DDR). Prior to Onxeo S.A., she was the Chief Medical Officer (CMO) at Epizyme, a clinical-stage company dedicated to developing novel epigenetic therapies for the treatment of cancer and other serious diseases. There, she led the global clinical development and regulatory strategy for tazemetostat. Before joining Epizyme, Dr. Agarwal held leadership positions in various domains including medical research, clinical development, clinical operations, and medical affairs. She was the CMO at SQZ Biotech, and held leadership roles at Curis and Tesaro. At Curis, she oversaw the Phase II study of its HDAC/PI3K dual inhibitor in diffuse large B-cell lymphoma (DLBCL) and the Phase I study of the oral checkpoint inhibitor in solid tumors. At Tesaro, she led the NDA and European Medicines Agency (EMA) submission for ZEJULA in ovarian cancer. Dr. Agarwal also held increasingly important positions at Covidien, AVEO, and Pfizer.

Dr. Agarwal has received numerous awards for her achievements and contributions in the field of drug development. In addition to her medical degree, she also holds a Master of Public Health (MPH) and a Master of Science in Business & IT (MS).